论文部分内容阅读
目的:分析甲地孕酮用于晚期肺癌化疗中的价值。方法:将68例晚期肺癌患者按照治疗方法不同随机分为两组,以采取单纯化疗的32例患者为对照组,以在化疗时加用甲地孕酮的36例患者为观察组,比较两组治疗效果及不良反应。结果:两组临床有效率、临床受益率组间无显著差异(P>0.05),观察组不良反应发生率27.8%明显低于对照组的68.8%,治疗后观察组生活质量评分明显高于对照组(P<0.05)。结论:在晚期肺癌化疗中加用甲地孕酮,可有效减少化疗不良反应,提高患者生活质量,值得推广。
Objective: To analyze the value of megestrol in chemotherapy of advanced lung cancer. Methods: Sixty-eight patients with advanced lung cancer were randomly divided into two groups according to the different treatment methods. Thirty-two patients with chemotherapy alone were selected as the control group. Thirty-six patients with megestrol combined with chemotherapy were selected as the observation group. Group treatment and adverse reactions. Results: There was no significant difference between the two groups in clinical efficiency and clinical benefit (P> 0.05). The incidence of adverse reactions in the observation group was significantly lower than that in the control group (27.8% vs 68.8%). After treatment, the quality of life scores of the observation group were significantly higher than those of the control group Group (P <0.05). Conclusion: The application of megestrol in chemotherapy of advanced lung cancer can effectively reduce the adverse reactions of chemotherapy and improve the quality of life of patients, which deserves promotion.